Volume 37, Issue 1 (January 1992)

    Analysis of Buprenorphine in Urine Specimens

    (Received 16 April 1991; accepted 7 May 1991)

    CODEN: JFSOAD

      Format Pages Price  
    PDF 8 $25   ADD TO CART


    Abstract

    The simultaneous determination of buprenorphine (Temgesic®) and its major metabolite, N-desalkylbuprenorphine, in urine samples has been studied. By using reversed-phase high-performance liquid chromatography (HPLC) with electrochemical detection, therapeutic concentrations of unconjugated buprenorphine down to 0.2 ng/mL, and 0.15 ng/mL for the metabolite, can be detected in urine samples. This method has been applied to a variety of urine samples from drug users. The possible analytical interference from several other regulated drugs has been studied. The results were also compared with those obtained from a commercial radioimmunoassay (RIA) test. This test is only capable of detecting buprenorphine concentrations higher than 1 ng/mL.


    Author Information:

    Debrabandere, L
    Pharmacist, chemist, and director, Laboratory of Toxicology, University of Louvain, Leuven,

    Van Boven, M
    Pharmacist, chemist, and director, Laboratory of Toxicology, University of Louvain, Leuven,

    Daenens, P
    Pharmacist, chemist, and director, Laboratory of Toxicology, University of Louvain, Leuven,


    Stock #: JFS13214J

    ISSN: 0022-1198

    DOI: 10.1520/JFS13214J

    ASTM International
    is a member of CrossRef.

    Author
    Title Analysis of Buprenorphine in Urine Specimens
    Symposium , 0000-00-00
    Committee E30